<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04297150</url>
  </required_header>
  <id_info>
    <org_study_id>SFC-NAC-2019-01</org_study_id>
    <nct_id>NCT04297150</nct_id>
  </id_info>
  <brief_title>Predictive Factors for Response to New Oral Anticoagulants in the Treatment of Non-valvular Atrial Fibrillation..</brief_title>
  <official_title>Identification of Clinical and Pharmacogenetic Factors Predictive of Response to New Oral Anticoagulants in the Treatment of Non-valvular Atrial Fibrillation.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación de Investigación Biomédica - Hospital Universitario de La Princesa</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundación de Investigación Biomédica - Hospital Universitario de La Princesa</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Post-authorization observational, prospective, follow-up study of a cohort of patients with
      non-valvular atrial fibrillation who are treated with direct oral anticoagulants (DOACs) to
      evaluate the clinical course (occurrence of stroke, major bleeding and mortality) and its
      correlation with clinical, pharmacokinetic (plasma concentrations), pharmacodynamic
      (haemostatic) and pharmacogenetic factors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Post-authorization observational, prospective, follow-up study of a cohort of patients with
      non-valvular atrial fibrillation treated with direct oral anticoagulants (dabigatran,
      rivaroxaban, apixaban and edoxaban) to assess the clinical course (occurrence of stroke,
      other ischemic or bleeding events and mortality) and its correlation with clinical,
      pharmacokinetic (plasma concentrations), pharmacodynamic (haemostatic) and pharmacogenetic
      factors.

      Patient selection and follow-up will be performed in 6 public Spanish hospitals: Hospital
      Universitario de la Princesa, Hospital Universitario La Paz, Hospital Universitario Ramón y
      Cajal, Fundación Jiménez Díaz, Hospital Gómez Ulla (Madrid) and Hospital Universitario de
      Burgos (Burgos). To reduce variability, the determination of anticoagulant activity will be
      performed in the Hematology Service of the Hospital Universitario de Burgos and the
      measurement of plasma concentrations and genotyping of all patients in the Clinical
      Pharmacology Service of the Hospital Universitario de la Princesa.

      Patients who are to receive or are receiving one of the four DOACs currently available in
      Spain will be informed about the characteristics of this study and will be asked to sign the
      consent form for their participation. The treatment or clinical management of these patients
      at each centre will not be modified. They will be asked three blood samples, coinciding with
      other tests that will be carried out to monitor their pathology (one blood sample for the
      study of the effect on coagulation, another for drug quantification in plasma and another for
      genetic studies) with the only requirement that they must have been treated with the drug for
      at least one week so that they have spent more than 5 half-lives and are in steady state. The
      samples will be extracted in the morning, before medication intake (trough concentrations).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 18, 2020</start_date>
  <completion_date type="Anticipated">October 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Major haemorrhages</measure>
    <time_frame>Throughout the follow-up, i.e. for at least 15 months and up to 30.</time_frame>
    <description>Occurrence of haemorrhages will be monitored throughout the follow-up, i.e. for at least 15 months and up to 30.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Haemorragic stroke</measure>
    <time_frame>Throughout the follow-up, i.e. for at least 15 months and up to 30.</time_frame>
    <description>Occurrence of haemorragic stroke will be monitored throughout the follow-up i.e. for at least 15 months and up to 30..</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ischemic stroke</measure>
    <time_frame>Throughout the follow-up, i.e. for at least 15 months and up to 30.</time_frame>
    <description>Occurrence of ischemic stroke will be monitored throughout the follow-up i.e. for at least 15 months and up to 30..</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death</measure>
    <time_frame>Throughout the follow-up, i.e. for at least 15 months and up to 30.</time_frame>
    <description>All-cause mortality will be monitored throughout the follow-up i.e. for at least 15 months and up to 30..</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">700</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Patients that satisfy inclusion criteria</arm_group_label>
    <description>Patients who satisfy the inclusion criteria and sign the informed consent.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apixaban</intervention_name>
    <description>Drug indicated for the treatment of NVAF</description>
    <arm_group_label>Patients that satisfy inclusion criteria</arm_group_label>
    <other_name>Eliquis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Edoxaban</intervention_name>
    <description>Drug indicated for the treatment of NVAF</description>
    <arm_group_label>Patients that satisfy inclusion criteria</arm_group_label>
    <other_name>Lixiana</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivaroxaban</intervention_name>
    <description>Drug indicated for the treatment of NVAF</description>
    <arm_group_label>Patients that satisfy inclusion criteria</arm_group_label>
    <other_name>Xarelto</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dabigatran</intervention_name>
    <description>Drug indicated for the treatment of NVAF</description>
    <arm_group_label>Patients that satisfy inclusion criteria</arm_group_label>
    <other_name>Pradaxa</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      One tube of blood for DNA extration and genotyping. One tube of blood for plasma extraction
      and drug determination. One tube of blood for the determination of anticoagulant activity.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Men and women over 18 years of age with NVAF requiring anticoagulant treatment with a DOAC.
        The prescription of the treatment will be previous and independent to the inclusion of the
        patient in the study. Patients who will initiate treatment (which will only be evaluated
        prospectively) and patients already in treatment (which will also be evaluated
        retrospectively) will be included.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Men or women over 18 years of age

          2. Patients with non-valvular atrial fibrillation.

          3. Patients who are going to receive or are receiving treatment with any of the DOACs
             (dabigatran, rivaroxaban, apixaban or edoxaban) for the prevention of stroke and
             systemic embolism in adult patients with NVFA, according to the drug label.

          4. Patients who agree to participate in the study and give their written consent.

        Exclusion Criteria:

          1. Pacientes en tratamiento con otros anticoagulantes.

          2. Pacientes que padezcan alguna enfermedad maligna o terminal cuya esperanza de vida sea
             inferior a 6 meses.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Francisco Abad Santos, MD, PhD</last_name>
    <phone>915202425</phone>
    <email>francisco.abad@salud.madrid.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gina Mejía Abril, MD</last_name>
    <phone>915202425</phone>
    <email>ginapaola.mejia@salud.madrid.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Universitario de Burgos</name>
      <address>
        <city>Burgos</city>
        <zip>09006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jorge Labrador Gómez, MD, PhD</last_name>
      <email>jlabradorg@saludcastillayleon.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de La Princesa</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gina Paola Mejía, MD</last_name>
      <phone>915202425</phone>
      <email>ginapaola.mejia@salud.madrid.org</email>
    </contact>
    <contact_backup>
      <last_name>Pablo Zubiaur Precioso, MPharm</last_name>
      <phone>915202425</phone>
      <email>pablo.zubiaur@salud.madrid.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hospital Gómez Ulla</name>
      <address>
        <city>Madrid</city>
        <zip>28028</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Martí Sánchez, MD, PhD</last_name>
      <email>docalcala@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>María Ángeles Gálvez Múgica, MD, PhD</last_name>
      <email>mariaangeles.galvez@salud.madrid.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Fundación Jiménez Díaz:</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lucia Llanos Jiménez, MD, PhD</last_name>
      <email>lucia.llanos@fjd.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Irene García García, MD</last_name>
      <email>irene.ucicec@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>February 18, 2020</study_first_submitted>
  <study_first_submitted_qc>March 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 5, 2020</study_first_posted>
  <last_update_submitted>July 15, 2020</last_update_submitted>
  <last_update_submitted_qc>July 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rivaroxaban</mesh_term>
    <mesh_term>Apixaban</mesh_term>
    <mesh_term>Edoxaban</mesh_term>
    <mesh_term>Dabigatran</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

